I have written three previous posts about GLP-1 drugs and their potential impact on our health, our behavior, and even familiar companies such as Weight Watchers. The more I have learned, the more significant these drugs appear to be.

But there is another question that cannot be avoided: What do GLP-1 drugs actually cost?

I am not a physician, pharmacist, insurance specialist, or pharmaceutical pricing expert. I am not attempting to tell anyone which drug to take or where to obtain it. I have, however, spent much of my professional life thinking about price, cost, and value. Those three things are related, but they are not the same.

And when it comes to GLP-1 drugs, they are definitely not the same.

One qualification is necessary at the outset. Everything that follows reflects information available in early September 2026. GLP-1 drugs, insurance coverage, government programs, and pricing are changing rapidly. Anything written today may be dated quickly. All we can do is make the best sense we can of the current information—and continue to watch the market.

One Drug—Many Prices

The official list price for Wegovy is about $1,350 per month. Zepbound has a list price of about $1,087 per month. Other GLP-1 drugs have similarly imposing sticker prices.

Those numbers are real, but many patients do not pay them. A commercially insured patient with coverage and a manufacturer’s savings card might pay $25 per month. An eligible Medicare beneficiary might pay $50 per month under the new Bridge Plan. Someone purchasing directly from a manufacturer might pay between $149 per month and $449 per month. An uninsured patient without access to one of these programs could still encounter a price approaching $1,000 per month or more.

And someone responding to a telehealth advertisement may discover that the prominently displayed price covers the membership—not the medicine.

The result is a pricing range extending from $25 per month to more than $1,000 per month for drugs that may contain the same active ingredient. So, what is the “price” of a GLP-1? The only honest answer may be: It depends.

The New Cash-Pay Market

The legitimate cash market for GLP-1 drugs has changed rapidly. According to Novo Nordisk’s current pricing information, Wegovy injections are available for $199 per month for the first two introductory-dose months and generally $349 per month thereafter. Wegovy pills range from $149 per month at the starting dose to $299 per month at higher doses.

Through LillyDirect, Zepbound begins at $299 per month, rising to $399 per month and then $449 per month as dosages increase. Lilly’s Foundayo pill ranges from $149 per month to approximately $349 per month, depending on dosage and temporary offers.

The distinction between list price and cash price is striking. A drug with a list price of $1,350 per month may be available directly from the manufacturer for $349 per month—or substantially less as an introductory dose.

The list price has begun to resemble the sticker price on new automobiles. It is important, but it does not necessarily tell us what anyone actually paid.

The Medicare GLP-1 Bridge

On July 1, 2026, the federal government’s Medicare GLP-1 Bridge began to provide certain weight-management drugs to eligible Medicare Part D beneficiaries with a copay of $50 per month. Covered drugs include Wegovy, Zepbound KwikPen, and Foundayo.

That $50 per month is the patient’s genuine out-of-pocket price for the medicine. It is not an introductory telehealth fee. But not every Medicare beneficiary qualifies. Eligibility generally requires a BMI of at least 35, or a lower BMI accompanied by specified medical conditions such as chronic kidney disease, uncontrolled hypertension, prediabetes, or prior cardiovascular events. Prior authorization is also required.

The program currently runs through December 31, 2027. For those who qualify, access at $50 per month could be life changing. For those who fall just outside the eligibility requirements, the difference between $50 per month and $349 per month may be equally significant.

What Are Ro and Weight Watchers Actually Selling?

Telehealth companies add another layer. Ro currently advertises its weight-management program for $39 for the first month. But that is the introductory membership fee—not the cost of a GLP-1 drug. After the first month, Ro’s membership costs between $74 per month and $149 per month, depending on whether the patient prepays for a longer period. The medication is billed separately.

A patient taking a maintenance dose of Wegovy through Ro might therefore pay $349 per month for the medicine plus $74 per month to $149 per month for membership and medical support. The total could be approximately $423 per month to $498 per month.

Weight Watchers has adopted a similar structure as it incorporates GLP-1 drugs into its traditional behavioral weight-loss programs. Its Med+ program currently advertises an introductory membership price of $25 per month for the first two months with a 12-month commitment. After that, the membership price increases to $74 per month for the remaining ten months. The cost of a GLP-1 drug is separate.

Weight Watchers is selling more than access to a prescription. Its program includes medical supervision, insurance assistance, nutrition counseling, behavioral support, workshops, and the familiar Weight Watchers app and community. That combination may have value, but the advertised membership price is not the patient’s total monthly cost.

The fine print may tell the whole truth. But it can be misleading to anyone not reading all of it.

What Are People Actually Paying?

Published evidence confirms that payments vary enormously. A 2025 study in JAMA Health Forum examined nearly 10,000 GLP-1 prescriptions. Among prescriptions that were filled, patients paid an average of approximately $72 for a 30-day supply. Patients treated for obesity without diabetes paid considerably more—about $134 for a 30-day supply on average.

But approximately 40% of the prescriptions were never filled. That creates a significant blind spot. Studies can measure what purchasers paid. They generally cannot tell us how many patients arrived at the pharmacy, heard the price, and went home without the medicine.

A broader 2026 study in the Journal of General Internal Medicine used federal expenditure data and found median out-of-pocket spending of $1,528 per year, or about $127 per month. Among people with at least two prescription fills, median spending was $2,070 per year. People 65 and older paid a median of $1,964 per year.

A late-2025 KFF survey adds the patient perspective. Some 56% of GLP-1 users said the drugs were difficult to afford, and 27% of insured users said they paid the full cost themselves. Among former users, 14% said they stopped because of cost.

These studies do not provide a single answer. They demonstrate why there is no single answer. Insurance helps many people, but the word “insured” does not necessarily mean that a particular drug, or its use for weight loss, is covered.

The Compounded and Gray Markets

During the GLP-1 shortages, compounded semaglutide and tirzepatide became widely available. Many patients obtained them through licensed prescribers and compounding pharmacies.

The shortages have ended, and the rules have tightened. Compounded drugs may still be appropriate in certain patient-specific circumstances, but they are not FDA-approved substitutes that can automatically be mass-produced whenever they are cheaper than the branded product.

Advertised prices for compounded products are often lower than branded cash prices, although comparisons are difficult because some prices include medical consultations, membership fees, laboratory work, and shipping while others do not. Beyond legitimate compounding lies a gray—and sometimes plainly illegal—market involving questionable online sellers, counterfeit products, and substances labeled “for research purposes.”

The FDA warns that such products may contain too much, too little, or none of the advertised ingredient. A bargain price for an unknown substance is not necessarily a bargain.

The Affordability Conundrum

The economics of GLP-1 drugs will continue to change. Competition is increasing. Pills are entering the market. Manufacturers are lowering cash prices. Medicare coverage is expanding. Insurers and employers are reconsidering their policies. Companies such as Weight Watchers are building medical and behavioral programs around the drugs.

People of some means who need these drugs can generally find a way to obtain them. Paying $200 per month, $300 per month, or even $500 per month is not pleasant, but it may be manageable—particularly when weighed against the potential health benefits.

But millions of Americans cannot afford an additional $100 per month, much less $300 per month or more. For them, the conundrum is stark: they cannot afford to pay for the drugs, but given the health consequences of obesity, diabetes, and related conditions, they may not be able to afford not to take them.

That tension will not disappear. It will likely create increasing pressure on the federal government, state governments, insurers, employers, and drug manufacturers to reduce prices or create additional ways for lower-income patients to obtain these medicines. The Medicare GLP-1 Bridge is one early response. More are likely to follow, and that pressure may continue pushing prices downward.

Living well and aging gratefully require us to be good stewards of our health and our financial resources. GLP-1 drugs may create enormous value for many people. The challenge now is making sure that their value is not reserved primarily for those who can afford the price of admission.

As always, be well, and age gratefully,

Chris

PS If you enjoy this post and the blog, consider telling your friends and sharing with your social media.  If you like it, they will probably like it, too.